Emerging common molecular pathways for primary dystonia
dc.contributor.author | LeDoux, Mark S. | en_US |
dc.contributor.author | Dauer, William T. | en_US |
dc.contributor.author | Warner, Thomas T. | en_US |
dc.date.accessioned | 2013-08-02T20:51:45Z | |
dc.date.available | 2014-08-01T19:11:42Z | en_US |
dc.date.issued | 2013-06-15 | en_US |
dc.identifier.citation | LeDoux, Mark S.; Dauer, William T.; Warner, Thomas T. (2013). "Emerging common molecular pathways for primary dystonia." Movement Disorders 28(7): 968-981. <http://hdl.handle.net/2027.42/99074> | en_US |
dc.identifier.issn | 0885-3185 | en_US |
dc.identifier.issn | 1531-8257 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/99074 | |
dc.description.abstract | The dystonias are a group of hyperkinetic movement disorders whose principal cause is neuron dysfunction at 1 or more interconnected nodes of the motor system. The study of genes and proteins that cause familial dystonia provides critical information about the cellular pathways involved in this dysfunction, which disrupts the motor pathways at the systems level. In recent years study of the increasing number of DYT genes has implicated a number of cell functions that appear to be involved in the pathogenesis of dystonia. A review of the literature published in English‐language publications available on PubMed relating to the genetics and cellular pathology of dystonia was performed. Numerous potential pathogenetic mechanisms have been identified. We describe those that fall into 3 emerging thematic groups: cell‐cycle and transcriptional regulation in the nucleus, endoplasmic reticulum and nuclear envelope function, and control of synaptic function. © 2013 Movement Disorder Society | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Nuclear Envelope | en_US |
dc.subject.other | Synaptic Function | en_US |
dc.subject.other | Endoplasmic Reticulum | en_US |
dc.subject.other | Cell Cycle | en_US |
dc.subject.other | DYT Genes | en_US |
dc.title | Emerging common molecular pathways for primary dystonia | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 23893453 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/99074/1/mds25547.pdf | |
dc.identifier.doi | 10.1002/mds.25547 | en_US |
dc.identifier.source | Movement Disorders | en_US |
dc.identifier.citedreference | Tolosa E, Compta Y. Dystonia in Parkinson's disease. J Neurol. 2006;( Suppl 7 ): VII7 – VII13. | en_US |
dc.identifier.citedreference | Augood SJ, Hollingsworth Z, Albers DS, et al. Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study. Neurology. 2002; 59: 445 – 458. | en_US |
dc.identifier.citedreference | Granata A, Watson R, Collinson L, Schiavo G, Warner TT. The dystonia‐associated protein torsinA modulates synaptic vesicle recycling. J Biol Chem. 2008; 283: 7568 – 7579. | en_US |
dc.identifier.citedreference | Granata A, Koo SJ, Haucke V, et al. CSN complex controls the stability of selected synaptic proteins via a torsinA‐dependent process. EMBO J. 2011; 30: 181 – 193. | en_US |
dc.identifier.citedreference | Kakazu Y, Koh J‐Y, Ho D, Gonzalez‐Alegre P, Harata C. Synaptic vesicle recycling is enhanced by torsinA that harbours the DYT1 dystonia mutation. Synapse. 2012; 66; 453 – 464. | en_US |
dc.identifier.citedreference | Kakazu Y, Koh J‐Y, Iwabuchi S, Gonzalez‐Alegre P, Harata C. Miniature release events of glutamate from hippocampal neurons are influenced by the dystonia‐associated protein TorsinA. Synapse. 2012; 66: 807 – 822. | en_US |
dc.identifier.citedreference | Pisani A, Martella G, Tscherter A, et al. Altered responses to dopaminergic D2 receptor activation and N‐type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia. Neurobiol Dis. 2006; 24: 318 – 325. | en_US |
dc.identifier.citedreference | Sciamanna G, Bonsi P, Tassone A, et al. Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia. Neurobiol Dis. 2009; 34: 133 – 145. | en_US |
dc.identifier.citedreference | Napolitano F, Pasqualetti M, Usiello A, et al. Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia. Neurobiol Dis. 2010; 38: 434 – 445. | en_US |
dc.identifier.citedreference | Asanuma K, Carbon‐Correll M, Eidelberg D. Neuroimaging in human dystonia. J Med Invest. 2005; 52: 272 – 279. | en_US |
dc.identifier.citedreference | Carbon M, Niethammer M, Peng S, et al. Abnormal striatal and thalamic dopamine neurotransmission: genotype‐related features of dystonia. Neurology. 2009; 72: 2097 – 2103. | en_US |
dc.identifier.citedreference | Carbon M, Argyelan M, Eidelberg D. Functional imaging in hereditary dystonia. Eur J Neurol. 2010;( Suppl 1 ): 58 – 64. | en_US |
dc.identifier.citedreference | Quatarone A, Pisani A. Abnormal synaptic plasticity in dystonia: disruption of synaptic homeostasis. Neurobiol Dis. 2011; 42: 162 – 170. | en_US |
dc.identifier.citedreference | Herve D, Le Moine C, Corvol JC, et al. Gα olf levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J Neurosci. 2001; 21: 4390 – 4399. | en_US |
dc.identifier.citedreference | Ashmore LJ, Hrizo SL, Paul SM, Van Voorhies WA, Beitel GJ, Palladino MJ. Novel mutations affecting the Na, K ATPase alpha model complex neurological diseases and implicate the sodium pump in increased longevity. Hum Genet. 2009; 126: 431 – 447. | en_US |
dc.identifier.citedreference | Calderon DP, Fremont R, Kraenzlin F, Khodakhah K. The neural substrates of rapid‐onset dystonia‐parkinsonism. Nat Neurosci. 2011; 14: 357 – 365. | en_US |
dc.identifier.citedreference | Kurian MA, Zhen J, Cheng S Y, et al. Homozygous loss‐of‐function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism‐dystonia. J Clin Invest. 2009; 119: 1595 – 1603. | en_US |
dc.identifier.citedreference | Kurian MA, Li Y, Zhen J, et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol. 2011; 10: 54 – 62. | en_US |
dc.identifier.citedreference | Vasudevan A, Breakefield XO, Bhide PG. Developmental patterns of torsinA and torsinB expression. Brain Res. 2006; 1073–1074: 139 – 145. | en_US |
dc.identifier.citedreference | Siegert S, Bahn C, Kramer ML, et al. TorsinA expression is detectable in human infants as young as 4 weeks old. Brain Res Dev Brain Res. 2005; 757: 19 – 26. | en_US |
dc.identifier.citedreference | Zhao Y, Xiao J, Gong S, Clara JA, Ledoux MD. Neural expression of transcription factor THAP1 during development in rat. Neuroscience. 2013; 231: 282 – 295. | en_US |
dc.identifier.citedreference | Phukan J Albanese A, Gasser T, Warner T. Primary dystonia and dystonia‐plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurol. 2011; 10: 1074 – 1085. | en_US |
dc.identifier.citedreference | Ozelius L, Kramer P, Page CE et al. The early‐onset torsion dystonia gene (DYT1) encodes an ATP‐binding protein. Nat Genet. 1997; 17: 40 – 48. | en_US |
dc.identifier.citedreference | Hanson PI, Whiteheart SW. AAA + proteins: have engine will work. Nat Rev Mol Cell. Biol. 2005; 6: 519 – 529. | en_US |
dc.identifier.citedreference | Kock N, Naismith TV, Boston HE, et al. Effects of genetic variations in the dystonia protein torsinA: identification of polymorphism at residue 216 as protein modifier. Hum Mol Genet. 2006; 15: 1355 – 1364. | en_US |
dc.identifier.citedreference | Augood SJ, Penney JB, Friberg IK, et al. Expression of the early onset torsion dystonia gene (DYT1) in human brain. Ann Neurol. 1998; 43: 669 – 673. | en_US |
dc.identifier.citedreference | Rostasy K, Augood SJ, Hewett JW, et al. TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiol Dis. 2003; 12: 11 – 24. | en_US |
dc.identifier.citedreference | Xiao J, Gong S, Zhao Y, LeDoux MS. Developmental expression of rat torsinA transcript and protein. Brain Res Dev Brain Res. 2004; 152: 47 – 60. | en_US |
dc.identifier.citedreference | Zhao Y, Xiao J, Ueda M, et al. Glial elements contribute to stress‐induced torsinA expression in the central and peripheral nervous systems. Neuroscience. 2008; 155: 439 – 453. | en_US |
dc.identifier.citedreference | Jungwirth M, Dear ML, Brown P, Holbrook K, Goodchild R. Relative expression of homologous torsinB correlates with the neuronal specific importance of DYT1 dystonia‐associated torsinA. Hum Mol Genet. 2010; 19: 888 – 900. | en_US |
dc.identifier.citedreference | Hersheson J, Menacci NE, Davis M, et al. Mutations in the autoregulatory domain of β‐tubulin 4a cause hereditary dystonia. Ann Neurol. 2012 [Epub ahead of print]. | en_US |
dc.identifier.citedreference | Blanchard A, Ea V, Roubertie A, et al. DYT6 dystonia: review of the literature and creation of the UMD Locus‐Specific Database (LSDB) for mutations in the THAP1 gene. Hum Mutat. 2011; 32: 1213 – 1224. | en_US |
dc.identifier.citedreference | LeDoux MS, Xiao J, Rudzińska M, et al. Genotype‐phenotype correlations in THAP1 dystonia: molecular foundations and description of new cases. Parkinsonism Relat Disord. 2012; 18: 414 – 425. | en_US |
dc.identifier.citedreference | Fuchs T, Gavarini S, Saunders‐Pullman R, et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet. 2009; 41: 286 – 288. | en_US |
dc.identifier.citedreference | Djarmati A, Schneider SA, Lohmann K, et al. Mutations in THAP1 (DYT6) and generalised dystonia with prominent spasmodic dysphonia: a genetic screening study. Lancet Neurol. 2009; 8: 447 – 452. | en_US |
dc.identifier.citedreference | Bressman SB, Raymond D, Fuchs T, Heiman GA, Ozelius LJ, Saunders‐Pullman R. Mutations in THAP1 (DYT6) in early‐onset dystonia: a genetic screening study. Lancet Neurol. 2009; 8: 441 – 446. | en_US |
dc.identifier.citedreference | Schneider SA, Ramirez A, Shafiee K, et al. Homozygous THAP1 mutations as cause of early‐onset generalized dystonia. Mov Disord. 2011; 26: 858 – 861. | en_US |
dc.identifier.citedreference | Roussigne M, Cayrol C, Clouaire T, Amalric F, Girard JP. THAP1 is a nuclear proapoptotic factor that links prostate‐apoptosis‐response‐4 (Par‐4) to PML nuclear bodies. Oncogene. 2003; 22: 2432 – 2442. | en_US |
dc.identifier.citedreference | Cayrol C, Lacroix C, Mathe C, et al. The THAP‐zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell‐cycle target genes. Blood. 2007; 109: 584 – 594. | en_US |
dc.identifier.citedreference | Zimprich A, Grabowski M, Asmus F, et al, T. Mutations in the gene encoding epsilon‐sarcoglycan cause myoclonus‐dystonia syndrome. Nat Genet. 2001; 29: 66 – 69. | en_US |
dc.identifier.citedreference | Sunada Y, Campbell KP. Dystrophin‐glycoprotein complex: molecular organization and critical roles in skeletal muscle. Curr Opin Neurol. 1995; 8: 379 – 384. | en_US |
dc.identifier.citedreference | Straub V, Campbell KP. Muscular dystrophies and the dystrophin‐glycoprotein complex. Curr Opin Neurol. 1997; 10: 168 – 175. | en_US |
dc.identifier.citedreference | Chan P, Gonzalez‐Maeso J, Ruf F, et al. Epsilon‐sarcoglycan immunoreactivity and mRNA expression in mouse brain. J Comp Neurol. 2005; 482: 50 – 75. | en_US |
dc.identifier.citedreference | Brunig I, Suter A, Knuesel I, Luscher B, Fritschy JM. GABAergic terminals are required for postsynaptic clustering of dystrophin but not of GABA(A) receptors and gephyrin. J Neurosci. 2002; 22: 4805 – 4813. | en_US |
dc.identifier.citedreference | Levi S, Grady RM, Henry MD, Campbell KP, Sanes JR, Craig AM. Dystroglycan is selectively associated with inhibitory GABAergic synapses but is dispensable for their differentiation. J Neurosci. 2002; 22: 4274 – 4285. | en_US |
dc.identifier.citedreference | Camargos S, Scholz S, Simon‐Sanchez J, et al. DYT16, a novel young‐onset dystonia‐parkinsonism disorder: identification of a segregating mutation in the stress response protein PRKRA. Lancet Neurol. 2008; 7: 207 – 215. | en_US |
dc.identifier.citedreference | Bragg DC, Armata IA, Nery FC, et al. Molecular pathways in dystonia. Neurobiol Dis. 2011; 42: 136 – 147. | en_US |
dc.identifier.citedreference | Xiao J, Uitti RJ, Zhao Y, et al. Mutations in CIZ1 cause adult‐onset primary cervical dystonia. Ann Neurol. 2012; 71: 458 – 469. | en_US |
dc.identifier.citedreference | Mitsui K, Matsumoto A, Ohtsuka S, et al. Cloning and characterization of a novel p21(Cip1/Waf1)‐interacting zinc finger protein, ciz1. Biochem Biophys Res Commun. 1999; 264: 457 – 464. | en_US |
dc.identifier.citedreference | Charlesworth G, Plagnol V, Holmstrom KM, et al. Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis. Am J Hum Genet. 2012; 91: 1041 – 1050. | en_US |
dc.identifier.citedreference | Fuchs T, Saunders‐Pullman R, Masuho I, et al. Mutations in GNAL cause primary torsion dystonia. Nat Genet. 2013; 45: 88 – 92. | en_US |
dc.identifier.citedreference | Vemula SR, Puschmann A, Xiao J, et al. Role of Gα(Olf) in familial and sporadic adult onset primary dystonia. Hum Mol Genet. 2013 [Epub ahead of print]. | en_US |
dc.identifier.citedreference | Coverley D, Marr J, Ainscough J. Ciz1 promotes mammalian DNA replication. J Cell Sci. 2005; 118: 101 – 112. | en_US |
dc.identifier.citedreference | Warder DE, Keherly MJ. Ciz1, Cip1 interacting zinc finger protein 1 binds the consensus DNA sequence ARYSR(0 2)YYAC. J Biomed Sci. 2003; 10: 406 – 417. | en_US |
dc.identifier.citedreference | Ainscough JF, Rahman FA, Sercombe H, et al. C‐terminal domains deliver the DNA replication factor Ciz1 to the nuclear matrix. J Cell Sci. 2007; 120: 115 – 124. | en_US |
dc.identifier.citedreference | Copeland NA, Sercombe HE, Ainscough JF, Coverley D. Ciz1 cooperates with cyclin‐A‐CDK2 to activate mammalian DNA replication in vitro. J Cell Sci. 2010; 123: 1108 – 1115. | en_US |
dc.identifier.citedreference | den Hollander P, Rayala SK, Coverley D, Kumar R. Ciz1, a novel DNA‐binding coactivator of the estrogen receptor alpha, confers hypersensitivity to estrogen action. Cancer Res. 2006; 66: 11021 – 11029. | en_US |
dc.identifier.citedreference | Bessiere D, Lacroix C, Campagne S, et al. Structure‐function analysis of the THAP zinc finger of THAP1, a large C2CH DNA‐binding module linked to Rb/E2F pathways. J Biol Chem. 2008; 283: 4352 – 4363. | en_US |
dc.identifier.citedreference | Campagne S, Saurel O, Gervais V, Milon A Structural determinants of specific DNA‐recognition by the THAP zinc finger. Nucleic Acids Res. 2010; 38: 3466 – 3476. | en_US |
dc.identifier.citedreference | Clouaire T, Roussigne M, Ecochard V, Mathe C, Amalric F, Girard JP. The THAP domain of THAP1 is a large C2CH module with zinc‐dependent sequence‐specific DNA‐binding activity. Proc Natl Acad Sci U S A. 2005; 102: 6907 – 6912. | en_US |
dc.identifier.citedreference | Sabogal A, Lyubimov AY, Corn JE, Berger JM, Rio DC THAP proteins target specific DNA sites through bipartite recognition of adjacent major and minor grooves. Nat Struct Mol Biol. 2010; 17: 117 – 123. | en_US |
dc.identifier.citedreference | Gavarini S, Cayrol C, Fuchs T, et al. Direct interaction between causative genes of DYT1 and DYT6 primary dystonia. Ann Neurol. 2010; 68: 549 – 553. | en_US |
dc.identifier.citedreference | Kaiser FJ, Osmanoric A, Rakovic et al. The dystonia gene DYT1 is repressed by the transcription factor THAP1 (DYT6). Ann Neurol. 2010; 68: 554 – 559. | en_US |
dc.identifier.citedreference | Palada V, Stiern S, Glockle et al, K. Lack of sequence variations in THAP1 gene and THAP1‐binding sites in TOR1A promoter of DYT1 patients. Mov Disord. 2012; 27: 917. | en_US |
dc.identifier.citedreference | Kamm C, Uflacker N, Asmus F, et al. No evidence for THAP1/DYT6 variants as disease modifiers in DYT1 dystonia. Mov Disord. 2011; 26: 2136 – 2137. | en_US |
dc.identifier.citedreference | Rual JF, Venkatesan K, Hao T, et al. Towards a proteome‐scale map of the human protein‐protein interaction network. Nature. 2005; 437: 1173 – 1178. | en_US |
dc.identifier.citedreference | Lütolf S, Radtke F, Aguet M, Suter U, Taylor V. Notch1 is required for neuronal and glial differentiation in the cerebellum. Development. 2002; 129: 373 – 385. | en_US |
dc.identifier.citedreference | Koekkoek SK, Yamaguchi K, Milojkovic BA, et al. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron. 2005; 47: 339 – 352. | en_US |
dc.identifier.citedreference | Andersson T, Södersten E, Duckworth JK, et al. CXXC5 is a novel BMP4‐regulated modulator of Wnt signaling in neural stem cells. J Biol Chem. 2009; 284: 3672 – 3681. | en_US |
dc.identifier.citedreference | Sadnicka A, Hoffland BS, Bhatia KP, van de Warrenburg BP, Edwards MJ. The cerebellum in dystonia—help or hindrance. Clin Neurophysiol. 2012; 123: 65 – 70. | en_US |
dc.identifier.citedreference | Evidente VG, Advincula J, Esteban R, et al. Phenomenology of “Lubag” or X‐linked dystonia‐parkinsonism. Mov Disord. 2002; 17: 1271 – 1277. | en_US |
dc.identifier.citedreference | Makino S, Kaji R, Ando S, et al. Reduced neuron‐specific expression of the TAF1 gene is associated with X‐linked dystonia‐parkinsonism. Am J Hum Genet. 2007; 80: 393 – 406. | en_US |
dc.identifier.citedreference | Sako W, Moridaki R, Kaji R, et al. Identification and localization of a neuron‐specific isoform of TAF1 in rat brain; implications for neuropathology of DYT3 dystonia. Neuroscience. 2011; 189: 100 – 107. | en_US |
dc.identifier.citedreference | Li HH, Li AG, Sheppard HM, Liu X. Phosphorylation on Thr‐55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Mol Cell. 2004; 13: 867 – 878. | en_US |
dc.identifier.citedreference | Buchmann AM, Skaar JR, DeCaprio JA. Activation of a DNA damage checkpoint response in a TAF1‐defective cell line. Mol Cell Biol. 2004; 24: 5332 – 5339. | en_US |
dc.identifier.citedreference | Katzenberger RJ, Marengo MS, Wassarman DA. ATM and ATR pathways signal alternative splicing of Drosophila TAF1 pre‐mRNA in response to DNA damage. Mol Cell Biol. 2006; 26: 9256 – 9267. | en_US |
dc.identifier.citedreference | Basham SE, Rose LS. The Caenorhabditis elegans polarity gene ooc‐5 encodes a Torsin‐related protein of the AAA ATPase superfamily. Development. 2001; 128: 4645 – 4656. | en_US |
dc.identifier.citedreference | Baptista MJ, O'Farrell C, Hardy J, Cookson MR. Microarray analysis reveals induction of heat shock proteins mRNAs by the torsion dystonia protein, TorsinA. Neurosci Lett. 2003; 343: 5 – 8. | en_US |
dc.identifier.citedreference | Koh YH, Rehfeld K, Ganetzky B. A Drosophila model of early onset torsion dystonia suggests impairment in TGF‐beta signaling. Hum Mol Genet. 2004; 13: 2019 – 2030. | en_US |
dc.identifier.citedreference | Erol A. Genotoxic stress‐mediated cell cycle activities for the decision of cellular fate. Cell Cycle. 2011; 10: 3239 – 3248. | en_US |
dc.identifier.citedreference | Aberle H, Haghighi AP, Fetter RD, McCabe BD, Magalhães TR, Goodman CS. wishful thinking encodes a BMP type II receptor that regulates synaptic growth in Drosophila. Neuron. 2002; 33: 545 – 558. | en_US |
dc.identifier.citedreference | McCabe BD, Marqués G, Haghighi AP, et al. The BMP homolog Gbb provides a retrograde signal that regulates synaptic growth at the Drosophila neuromuscular junction. Neuron. 2003; 39: 241 – 254. | en_US |
dc.identifier.citedreference | Saunders‐Pullman R, Raymond D, Stoessl AJ, et al. Variant ataxia‐telangiectasia presenting as primary‐appearing dystonia in Canadian Mennonites. Neurology. 2012; 78: 649 – 657. | en_US |
dc.identifier.citedreference | Pommier Y, Weinstein JN, Aladjem MI, Kohn KW. Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin Cancer Res. 2006; 12: 2657 – 2661. | en_US |
dc.identifier.citedreference | Bertran‐Gonzalez J, Håkansson K, Borgkvist A, et al. Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons. Neuropsychopharmacology. 2009; 34: 1710 – 1720. | en_US |
dc.identifier.citedreference | Herrup K, Sunter K. Numerical matching during cerebellar development: quantitative analysis of granule cell death in staggerer mouse chimeras. J Neurosci. 1987; 7: 829 – 836. | en_US |
dc.identifier.citedreference | Subkhankulova T, Zhang X, Leung C, Marino S. Bmi1 directly represses p21Waf1/Cip1 in Shh‐induced proliferation of cerebellar granule cell progenitors. Mol Cell Neurosci. 2010; 45: 151 – 162. | en_US |
dc.identifier.citedreference | Wang L, Wang R, Herrup K. E2F1 works as a cell cycle suppressor in mature neurons. J Neurosci. 2007; 27: 12555 – 12564. | en_US |
dc.identifier.citedreference | Li J, Chen J, Vinters HV, Gatti RA, Herrup K. Stable brain ATM message and residual kinase‐active ATM protein in ataxia‐telangiectasia. J Neurosci. 2011; 31: 7568 – 7577. | en_US |
dc.identifier.citedreference | Prudente CN, Pardo CA, Xiao J, et al. Neuropathology of cervical dystonia. Exp Neurol. 2013; 241: 95 – 104. | en_US |
dc.identifier.citedreference | Song CH, Bernhard D, Bolarinwa C, Hess EJ, Smith Y, Jinnah HA. Subtle microstructural changes of the striatum in a DYT1 knock‐in mouse model of dystonia. Neurobiol Dis. 2013; 54: 362 – 371. | en_US |
dc.identifier.citedreference | Torres GE, Sweeney AL, Beaulieu JM, Shashidharan P, Caron MG. Effect of torsinA on membrane proteins reveals a loss of function and a dominant‐negative phenotype of the dystonia‐associated DeltaE‐torsinA mutant. Proc Natl Acad Sci U S A. 2004; 101: 15650 – 15655. | en_US |
dc.identifier.citedreference | Hewett JW, Tannous B, Niland BP, et al. Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proc Natl Acad Sci U S A. 2007; 104: 7271 – 7276. | en_US |
dc.identifier.citedreference | Hewett JW, Nery FC, Niland B, et al. siRNA knock‐down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells. Hum Mol Genet. 2008; 17: 1436 – 1445. | en_US |
dc.identifier.citedreference | Chen P, Burdette AJ, Porter JC, et al. The early‐onset torsion dystonia‐associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. Hum Mol Genet. 2010; 19: 3502 – 3515. | en_US |
dc.identifier.citedreference | Nery FC, Armata IA, Farley JE, et al. TorsinA participates in endoplasmic reticulum‐associated degradation. Nat Commun. 2011; 2: 393. | en_US |
dc.identifier.citedreference | Bernasconi R, Molinari M. ERAD and ERAD tuning: disposal of cargo and of ERAD regulators from the mammalian ER. Curr Opin Cell Biol. 2011; 23: 176 – 183. | en_US |
dc.identifier.citedreference | Lee ES, Tang N, Thompson S, Miller S, Katze MG. The double‐stranded RNA‐activated protein kinase (PKR) plays a significant role in a sustained ER stress‐induced apoptosis. FEBS J. 2007; 581: 4325 – 4332. | en_US |
dc.identifier.citedreference | Gerace, L. TorsinA and torsion dystonia: unraveling the architecture of the nuclear envelope. Proc Natl Acad Sci U S A. 2004; 101: 8839 – 8840. | en_US |
dc.identifier.citedreference | Goodchild RE, Dauer WT. Mislocalization to the nuclear envelope: an effect of the dystonia‐causing torsinA mutation. Proc Natl Acad Sci U S A. 2004; 101: 847 – 852. | en_US |
dc.identifier.citedreference | Goodchild RE, Kim, CE, Dauer WT. Loss of the dystonia‐associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron. 2005; 48: 923 – 932. | en_US |
dc.identifier.citedreference | Naismith TV, Heuser JE, Breakefield XO, Hanson PI. TorsinA in the nuclear envelope. Proc Natl Acad Sci U S A. 2004; 101: 7612 – 7617. | en_US |
dc.identifier.citedreference | Gonzalez‐Alegre P, Paulson HL. Aberrant cellular behavior of mutant torsinA implicates nuclear envelope dysfunction in DYT1 dystonia. J Neurosci. 2004; 24: 2593 – 2601. | en_US |
dc.identifier.citedreference | Giles LM, Chen J, Li L, Chin LS. Dystonia‐associated mutations cause premature degradation of torsinA protein and cell‐type‐specific mislocalization to the nuclear envelope. Hum Mol Genet. 2008; 17: 2712 – 2722. | en_US |
dc.identifier.citedreference | Goodchild RE, Dauer WT. The AAA+ protein torsinA interacts with a conserved domain present in LAP1 and a novel ER protein. J Cell Biol. 2005; 168: 855 – 862. | en_US |
dc.identifier.citedreference | Worman HJ, Gundersen GG. Here come the SUNs: a nucleocytoskeletal missing link. Trends Cell Biol. 2006; 16: 67 – 69. | en_US |
dc.identifier.citedreference | Nery FC, Zeng J, Niland et al. TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton. J Cell Sci. 2008; 121: 3476 – 3486. | en_US |
dc.identifier.citedreference | Esapa CT, Waite A, Locke M, et al. SGCE missense mutations that cause myoclonus‐dystonia syndrome impair epsilon‐sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA. Hum Mol Genet. 2007; 16: 327 – 342. | en_US |
dc.identifier.citedreference | Ferrari‐Toninelli G, Paccioretti S, Francisconi S, Uberti D, Memo M. TorsinA negatively controls neurite outgrowth of SH‐SY5Y human neuronal cell line. Brain Res. 2004; 1012: 75 – 81. | en_US |
dc.identifier.citedreference | Hewett JW, Zeng J, Niland BP, Bragg DC, Breakefield XO. Dystonia‐causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. Neurobiol Dis. 2006; 22: 98 – 111. | en_US |
dc.identifier.citedreference | Srsen V, Korfali N, Schirmer EC. Nuclear envelope influences on cell‐cycle progression. Biochem Soc Trans. 2011; 39: 1742 – 1746. | en_US |
dc.identifier.citedreference | Egecioglu D, Brickner JH. Gene positioning and expression. Curr Opin Cell Biol. 2011; 23: 338 – 345. | en_US |
dc.identifier.citedreference | Ichinose H, Ohye T, Takahashi E, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet. 1994; 8: 236 – 242. | en_US |
dc.identifier.citedreference | Knappskog PM, Flatmark T, Mallet J, Ludecke B, Bartholome K. Recessively inherited L‐DOPA‐responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet. 1995; 4: 1209 – 1212. | en_US |
dc.identifier.citedreference | Trender‐Gerhard I, Sweeney MG, Schwingenschuh P, et al. Autosomal‐dominant GTPCH1‐deficient DRD: clinical characteristics and long‐term outcome of 34 patients. J Neurol Neurosurg Psychiatry. 2009; 80: 839 – 845. | en_US |
dc.identifier.citedreference | Casey DE. Pathophysiology of antipsychotic drug‐induced movement disorders. J Clin Psychiatry. 2004; 65: 25 – 28. | en_US |
dc.identifier.citedreference | Egami K, Yitta S, Lewers JC, et al. Basal ganglia dopamine loss due to defect in purine cycling. Neurobiol Dis. 2007; 26: 391 – 407. | en_US |
dc.identifier.citedreference | Perlmutter JS, Stambuk MK, Markham J, et al. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci. 1997; 17: 843 – 850. | en_US |
dc.identifier.citedreference | Misbahuddin A, Placzek MR, Chaudhuri KR, Wood NW, Bhatia KP, Warner TT. A polymorphism in the dopamine receptor DRD5 is associated with blepharospasm. Neurology. 2002; 58: 124 – 126. | en_US |
dc.identifier.citedreference | Augood SJ, Martin DM, Ozelius LJ, Breakefield XO, Penney JB Jr, Standaert DG. Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain. Ann Neurol. 1999; 46: 761 – 769. | en_US |
dc.identifier.citedreference | Augood SJ, Hollingsworth Z, Albers DS, et al. Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study. Neurology. 2002; 59: 445 – 458. | en_US |
dc.identifier.citedreference | Furukawa Y, Hornykiewicz O, Fahn S, Kish SJ. Striatal dopamine in early‐onset primary torsion dystonia with the DYT1 mutation. Neurology. 2000; 54: 1193 – 1195. | en_US |
dc.identifier.citedreference | Shashidharan P, Sandu D, Potla U, et al. Transgenic mouse model of early‐onset DYT1 dystonia. Hum Mol Genet. 2005; 14: 125 – 133. | en_US |
dc.identifier.citedreference | Dang MT, Yokoi F, McNaught KS, et al. Generation and characterization of Dyt1 DeltaGAG knock‐in mouse as a model for early‐onset dystonia. Exp Neurol. 2005; 196: 452 – 463. | en_US |
dc.identifier.citedreference | Grundmann K, Hubener J, Habig K, et al. Gene expression changes in a transgenic mouse model overexpressing human wild‐type and mutant torsinA. Proteomics Clin Appl. 2008; 2: 720 – 736. | en_US |
dc.identifier.citedreference | Zhao Y, Decuypere M, Ledoux MS. Abnormal motor function and dopamine neurotransmission in DYT1 DeltaGAG transgenic mice. Exp Neurol. 2008; 210: 719 – 730. | en_US |
dc.identifier.citedreference | Page ME, Bao L, Andre P, et al. Cell‐autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice. Neurobiol Dis. 2010; 39: 318 – 326. | en_US |
dc.identifier.citedreference | Balcioglu A, Kim M‐O, Sharma N, Cha J‐H, Breakefield XO, Standaert DG. Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem. 2007; 102: 783 – 788. | en_US |
dc.identifier.citedreference | Hewett J, Johanson P, Sharma N, Standaert DG, Balcioglu A. Function of dopamine transporter is compromised in DYT1 transgenic animal model in vivo. J Neurochem. 2010; 113: 228 – 235. | en_US |
dc.identifier.citedreference | Song CH, Fan X, Exeter CJ, Hess EJ, Jinnah HA. Functional analysis of Dopaminergic system in a DYT1 knock‐in mouse model of dystonia. Neurobiol Dis. 2012; 48: 66 – 78. | en_US |
dc.identifier.citedreference | Misbahuddin A, Placzek MR, Taanman JW, et al. Mutant torsinA, which causes early‐onset primary torsion dystonia, is redistributed to membranous structures enriched in vesicular monoamine transporter in cultured human SH‐SY5Y cells. Mov Disord. 2005; 20: 432 – 440. | en_US |
dc.identifier.citedreference | Bao L, Patel JC, Walker RH, Shashidharan P, Rice ME. Dysregulation of striatal dopamine release in a mouse model of dystonia. J Neurochem. 2010; 114: 1781 – 1791. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.